Page 163 - Binder2

You can see here the dramatic difference between immune
activation in the placebo and in the treatment. This study
doesn’t include data on ADAs for the simple reason that
gluten isn’t a “drug” per say and therefore can’t have anti-
drug antibodies.

What you’ll see is there is a pretty significant difference in
almost every category they tested. This incredibly
important, what this tells us is that this drug, and this
platform is widely effective. This is exactly the kind of
platform we’ve been describing throughout this chapter:

• Targeted
• Durable
• Tolerogenic by design
• Delivered in a context the immune system
understands

Why COUR Matters

COUR is not alone—but it is early.
And what makes it important to this discussion isn’t just the
science—it’s the blueprint.

The company exemplifies what a next-generation biologic
developer could look like:

• One that treats immune compatibility as a design
input, not a Phase III surprise
• One that leverages natural tolerance pathways
instead of bypassing them
• One that proves immunomodulation can be precise,
antigen-specific, and platformizable

161